Amedeo Smart

Free Medical Literature Service

 

Amedeo

Lung Cancer
  Free Subscription

08.09.2025

1 Ann Oncol
2 Ann Surg Oncol
2 Ann Thorac Surg
5 BMC Cancer
2 BMJ
2 Cancer
1 Cancer Lett
3 Cancer Res
2 Cancer Sci
1 Chest
6 Clin Lung Cancer
2 Clin Nucl Med
1 Eur J Cancer
1 Eur J Cardiothorac Surg
1 Int J Cancer
1 Int J Radiat Oncol Biol Phys
1 J Clin Invest
2 J Thorac Cardiovasc Surg
1 JAMA Oncol
3 Lung Cancer
1 Mol Cancer Ther
1 Oncol Rep
2 Oncologist
2 PLoS One
1 Proc Natl Acad Sci U S A


    Ann Oncol

  1. ZER A, Ahn MJ, Barlesi F, Bubendorf L, et al
    Early and locally advanced non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-updagger.
    Ann Oncol. 2025 Aug 22:S0923-7534(25)00923-8. doi: 10.1016/j.annonc.2025.
    >> Share


    Ann Surg Oncol

  2. LIU J, Zhou P
    ASO Author Reflections: Predictors of Unrecovered Early Post-Discharge Pain after Thoracoscopic Sublobar Resection for Stage IA Lung Cancer.
    Ann Surg Oncol. 2025 Sep 2. doi: 10.1245/s10434-025-18231.
    >> Share

  3. CHENG JJ, Dai ZY, Wang FQ, Zhang HL, et al
    ASO Visual Abstract: Analysis of Individual Patient Data Demonstrates that Sublobar Resection Followed by Adjuvant Chemotherapy has Equivalent Prognosis to Lobectomy in Stage I Non-Small Cell Lung Cancer Patients with Spread Through Air Spaces.
    Ann Surg Oncol. 2025 Sep 5. doi: 10.1245/s10434-025-18289.
    >> Share


    Ann Thorac Surg

  4. BRANDT WS, Rossetti NE, Eaton DB, Samson P, et al
    Synchronous Primary Early-Stage Non-Small Cell Lung Cancer: Trends in Management and Factors Associated with Improved Survival.
    Ann Thorac Surg. 2025 Sep 2:S0003-4975(25)00843.
    >> Share

  5. MOTT NM, Meguid RA, Fendrick AM
    Securing Lung Cancer Screening, The First Step.
    Ann Thorac Surg. 2025 Sep 2:S0003-4975(25)00836.
    >> Share


    BMC Cancer

  6. MANIWA H, Naito M, Ono M, Suyama N, et al
    Decreased 6-minute walk distance after pulmonary resection increases the risk of postoperative hospital re-admission: a retrospective cohort study.
    BMC Cancer. 2025;25:1397.
    >> Share

  7. HE Y, Che S, Xie J, Zhu W, et al
    Relationships between growth rate and Ki-67 and immune indices in ground-glass nodule-featured lung adenocarcinoma.
    BMC Cancer. 2025;25:686.
    >> Share

  8. LI L, Feng Q, Jiang Y, Yang L, et al
    KRAS mutation promotes immune escape of lung adenocarcinoma via ZNF24/SLC7A5/PD-L1 axis.
    BMC Cancer. 2025;25:1417.
    >> Share

  9. LIU X, Lu F, Yang H, Liao G, et al
    Effectiveness and safety of pirfenidone for radiation-induced lung injury in non-small cell lung cancer: a retrospective pilot study.
    BMC Cancer. 2025;25:1415.
    >> Share

  10. MCMILLAN MT, Reyngold M, Crane CH, O'Brien DAR, et al
    A phase II trial of hepatic ablation of metastases to modulate and enhance immunotherapy response in non-small cell lung cancer (HAMMER-NSCLC).
    BMC Cancer. 2025;25:1408.
    >> Share


    BMJ

  11. ZHANG J, Liu X, Xu Y
    Cardiovascular toxicity risks in treating EGFR-mutated lung cancer.
    BMJ. 2025;390:r1834.
    >> Share

  12. MA Z, Cao F, Liao M, Min R, et al
    Cardiovascular adverse events associated with epidermal growth factor receptor tyrosine kinase inhibitors in EGFR-mutated non-small cell lung cancer: systematic review and network meta-analysis.
    BMJ. 2025;390:e082834.
    >> Share


    Cancer

  13. VOLK RJ, Lettieri JS, Leal VB, Duhon GF, et al
    The quality of patient decision aids for lung cancer screening: Results from an environmental scan.
    Cancer. 2025;131:e70008.
    >> Share

  14. HUANG L, Zeng F, Huang P, Ren D, et al
    Mutational landscape and tyrosine kinase inhibitor sensitivity in EGFR L833 and H835 mutated non-small cell lung cancer.
    Cancer. 2025;131:e70063.
    >> Share


    Cancer Lett

  15. CHEN Z, Vallega KA, Wang D, Bildtsen E, et al
    Targeting MKK3/c-Myc interaction to overcome osimertinib acquired resistance in EGFR mutant lung cancer.
    Cancer Lett. 2025;633:218010.
    >> Share


    Cancer Res

  16. WU CP, Vaishnavi A
    Another Slice of the Pie Uncovered: RIT1M90I Is an Actionable Driver in Non-Small Cell Lung Cancer.
    Cancer Res. 2025;85:3186-3188.
    >> Share

  17. DIMARCO AV, Ravichandran M, Lau J, Lima A, et al
    RIT1M90I Is a Driver of Lung Adenocarcinoma Tumorigenesis and Resistance to Targeted Therapy.
    Cancer Res. 2025;85:3207-3218.
    >> Share

  18. MOZZARELLI AM, Cuevas-Navarro A, Shuldiner EG, Vega M, et al
    RIT1 Drives Oncogenic Transformation and Is an Actionable Target in Lung Adenocarcinoma.
    Cancer Res. 2025;85:3196-3206.
    >> Share


    Cancer Sci

  19. HORI K, Tanaka I, Sato T, Sato M, et al
    PBK Expression Promotes the Aggressive Phenotypes of Mesothelioma.
    Cancer Sci. 2025;116:2413-2426.
    >> Share

  20. YANG W, Wu X, Cai F, Guo Z, et al
    NFATc4 Promotes Lung Adenocarcinoma Progression via the CCNB1/CDK1 Pathway and Is a Potential Prognostic Biomarker.
    Cancer Sci. 2025;116:2400-2412.
    >> Share


    Chest

  21. RIVERA MP, Benefield T, Durham DD, Lund JL, et al
    Comparison of Underlying Risk of Developing and Dying from Lung Cancer in Screened Populations.
    Chest. 2025 Sep 3:S0012-3692(25)05147-5. doi: 10.1016/j.chest.2025.
    >> Share


    Clin Lung Cancer

  22. DEEK RA, Kim J, Kumar R, Medina B, et al
    Clinical and Genomic Features and Prognostic Biomarkers of Oligometastatic Nonsmall Cell Lung Cancer.
    Clin Lung Cancer. 2025 Jul 31:S1525-7304(25)00153.
    >> Share

  23. SUN F, Nagpal S, Singhal S, Neal JW, et al
    Brief Report: Safety of Pulse-Dose Osimertinib for Treatment of Leptomeningeal Disease or Refractory Brain Metastases in EGFR-Mutated Nonsmall Cell Lung Cancer.
    Clin Lung Cancer. 2025 Aug 6:S1525-7304(25)00165.
    >> Share

  24. VAKKALAGADDA CV, Bucheit L, Clemens K, Saha J, et al
    Impact of Incidental Germline BRCA1/2 and PALB2 Alterations on EGFR Monotherapy Real-World Outcomes for Patients With Advanced Non-Small-Cell Lung Cancer.
    Clin Lung Cancer. 2025 Aug 5:S1525-7304(25)00151.
    >> Share

  25. REINMUTH N, Goldman JW, Chen Y, Hotta K, et al
    Durvalumab Plus Platinum-Etoposide in Extensive-Stage Small-Cell Lung Cancer: Outcomes in Age, Sex, and Platinum Subgroups From the Phase 3 CASPIAN Study.
    Clin Lung Cancer. 2025 Aug 6:S1525-7304(25)00164.
    >> Share

  26. CAO W, Duan H, Shao C, Yan X, et al
    Achieving an Objective Response Following Two Cycles of Neoadjuvant Chemotherapy Plus Anti-PD-(L)1 Inhibitors Might Predict the Optimal Pathological Response in Resectable Stage II-III Nonsmall Cell Lung Cancer.
    Clin Lung Cancer. 2025 Aug 9:S1525-7304(25)00178.
    >> Share

  27. DANESE MD, Shafrin J, Laurie M, Korytowsky B, et al
    Imaging Utilization and Treatment Patterns of Brain Metastases in Patients With Non-Small Cell Lung Cancer: A SEER-Medicare and SEER Database Analysis.
    Clin Lung Cancer. 2025 Jul 29:S1525-7304(25)00163.
    >> Share


    Clin Nucl Med

  28. ZHOU J, Zhou M, Chen W, Liu Y, et al
    68Ga-NODAGA-SNA006 PET/CT Imaging of Tumor CD8+ T-Cell Infiltration Predicts Immunotherapy Response in Lung Cancer.
    Clin Nucl Med. 2025 Sep 1. doi: 10.1097/RLU.0000000000006098.
    >> Share

  29. AMINI M, Hajianfar G, Salimi Y, Mansouri Z, et al
    MetaPredictomics: A Comprehensive Approach to Predict Postsurgical Non-Small Cell Lung Cancer Recurrence Using Clinicopathologic, Radiomics, and Organomics Data.
    Clin Nucl Med. 2025 Sep 3. doi: 10.1097/RLU.0000000000006086.
    >> Share


    Eur J Cancer

  30. TSUKAGUCHI A, Matsumoto K, Tamiya A, Tamiya M, et al
    Timing of first pembrolizumab infusion and long-term outcomes in non-small cell lung cancer: A retrospective multicenter study.
    Eur J Cancer. 2025;228:115748.
    >> Share


    Eur J Cardiothorac Surg

  31. ARMAND E, Fourdrain A, Todesco A, Brioude G, et al
    Outcomes of non-small cell lung cancer resection in patients with synchronous brain metastases.
    Eur J Cardiothorac Surg. 2025 Sep 2:ezaf292. doi: 10.1093.
    >> Share


    Int J Cancer

  32. CHEN T, Wang W, Qian Y, Wang M, et al
    Immune checkpoint inhibitors combined with anti-angiogenic therapy as second- or further-line treatment for small cell lung cancer: Efficacy, safety, and prognostic biomarkers.
    Int J Cancer. 2025 Sep 1. doi: 10.1002/ijc.70102.
    >> Share


    Int J Radiat Oncol Biol Phys

  33. RUTKOWSKI J, Nowicka Z, Sobocki BK, Slebioda T, et al
    Patterns of immunity changes predict response to stereotactic ablative radiotherapy in early non-small-cell lung cancer.
    Int J Radiat Oncol Biol Phys. 2025 Sep 3:S0360-3016(25)06206.
    >> Share


    J Clin Invest

  34. KRATZMEIER C, Taheri M, Mei Z, Lim I, et al
    Lung adenocarcinoma-derived IFN-gamma promotes growth by modulating CD8+ T cell production of CCR5 chemokines.
    J Clin Invest. 2025;135:e191070.
    >> Share


    J Thorac Cardiovasc Surg

  35. CASO R, Zhou N, Skovgard M, Toumbacaris N, et al
    Lobectomy Improves Disease-Free Survival Over Sublobar Resection for High-Risk Stage IA Non-Small Cell Lung Cancer.
    J Thorac Cardiovasc Surg. 2025 Aug 29:S0022-5223(25)00678.
    >> Share

  36. PAN G, Yang G, Wang W, Liu H, et al
    Resection for stage IV non-small cell lung cancer: Beyond the extent of resection.
    J Thorac Cardiovasc Surg. 2025 Sep 4:S0022-5223(25)00658.
    >> Share


    JAMA Oncol

  37. JONGBLOED M, Bortolot M, Willmann J, Bartolomeo V, et al
    Current Controversies and Challenges in Non-Oncogene-Addicted Synchronous Oligometastatic Non-Small Cell Lung Cancer: A Review.
    JAMA Oncol. 2025 Sep 4. doi: 10.1001/jamaoncol.2025.2891.
    >> Share


    Lung Cancer

  38. SHAO T, Yang J, Chen J, Zhang Y, et al
    Retraction notice to "Antibody-drug conjugate components in association with the incidence of ADC-related interstitial lung disease: A systematic review and meta-analysis". [Lung Cancer 204 (2025) 108559].
    Lung Cancer. 2025 Aug 31:108719. doi: 10.1016/j.lungcan.2025.108719.
    >> Share

  39. VILLALOBOS M, Ludwig JO, Konig M, Unsold L, et al
    Communication about personal values of patients with advanced lung cancer in the hospital: results of a mixed-methods study.
    Lung Cancer. 2025;208:108729.
    >> Share

  40. HUIJS JWJ, Sadowska AM, Degens JHRJ, Steendam CMJ, et al
    Clinical risk factors for developing brain metastases during first-line (chemo-)immunotherapy in patients with non-small cell lung cancer without known baseline brain metastases.
    Lung Cancer. 2025;208:108745.
    >> Share


    Mol Cancer Ther

  41. PATEL UA, Shi MY, Kazan JM, Nixon KCJ, et al
    CRISPR Screen Identifies HDAC3 as a Novel Radiosensitizing Target in Small Cell Lung Cancer.
    Mol Cancer Ther. 2025 Sep 3. doi: 10.1158/1535-7163.MCT-24-0861.
    >> Share


    Oncol Rep

  42. LV Q, Xu J, Hu N, Zhao Y, et al
    Lactylation modification in lung cancer: A review of current research and future directions (Review).
    Oncol Rep. 2025;54:148.
    >> Share


    Oncologist

  43. LIANG J, Waliany S, Do A, Peterson JL, et al
    ENIGMA+: a national, decentralized, remote consent study for clinical data and biospecimen collection in patients with ALK-positive advanced NSCLC.
    Oncologist. 2025;30:oyaf217.
    >> Share

  44. LI X, Gong W, Yao X, Gao Y, et al
    Effects of magnesium concentration on the regulation of nutrition and inflammation in nutritional support for cancer patients.
    Oncologist. 2025;30:oyaf211.
    >> Share


    PLoS One

  45. ZENG Q, Hu T, Chen Z, Zheng J, et al
    YOLO-ED: An efficient lung cancer detection model based on improved YOLOv8.
    PLoS One. 2025;20:e0330732.
    >> Share

  46. ARIK A, Cairns AJG, Streftaris G
    Cancer disparities: Projection, COVID-19, and scenario-based diagnosis delay impact.
    PLoS One. 2025;20:e0330752.
    >> Share


    Proc Natl Acad Sci U S A

  47. ZHANG J, Zhang J, Han L, Wu S, et al
    Inflammation awakens dormant cancer cells by modulating the epithelial-mesenchymal phenotypic state.
    Proc Natl Acad Sci U S A. 2025;122:e2515009122.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016